


ABSTRACT**HETEROCYCLIC AMIDE DERIVATIVES AS
INHIBITORS OF GLYCOGEN PHOSPHORYLASE**

Heterocyclic amides of formula (1)



(1)

wherein:

X is N or CH;

R⁴ and R⁵ together are either -S-C(R⁶)=C(R⁷)- or -C(R⁷)=C(R⁶)-S-;

R⁶ and R⁷ are independently selected from, for example hydrogen, halo and C₁₋₄alkyl;

A is phenylene or heteroarylene;

n is 0, 1 or 2;

R¹ is selected from for example halo, nitro, cyano, hydroxy, carboxy;

R² is hydrogen, hydroxy or carboxy;

R³ is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and

C₁₋₄alkyl (optionally substituted by 1 or 2 R⁸ groups);

R⁸ is selected from for example hydroxy, -COCOOR⁹, -C(O)N(R⁹)(R¹⁰), -NHC(O)R⁹, (R⁹)(R¹⁰)N- and -COOR⁹;

R⁹ and R¹⁰ are selected from for example hydrogen, hydroxy, C₁₋₄alkyl (optionally substituted by 1 or 2 R¹³);

R¹³ is selected from hydroxy, halo, trihalomethyl and C₁₋₄alkoxy;

or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.